The European Commission has awarded a 50,000-euro grant to Latvian company Latima for commercialisation of a cancer virotherapy medicine in the EU markets.
Latima, a company of Rigvir holding, which develops and promotes cancer virotherapy around the world, was given the grant through the EU’s Horizon 2020 programme “Dedicated support to biotechnology SMEs closing the gap from lab to market,” Rigvir’s CFO Karlis Urbans disclosed.
“There are millions of cancer patients around the world who are in need of this unique cancer m...
The article you requested can be accessed only by subscribing to the online version of The Baltic Times. If you are already subscribed to The Baltic Times, please authorize yourself.
In case you don't have a subscription yet - please visit our SUBSCRIPTION